Haemonetics Corporation share price logo

Haemonetics Corporation

NASDAQ: HAE

Mid Cap

$87.84

+2.82

(+3.32%)

as on

Haemonetics Corporation Stock Performance

as on August 8, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $84.92
    $87.68
    downward going graph

    3.32%

    Downside

    -0.18%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $47.32
    $88.59
    downward going graph

    46.14%

    Downside

    0.85%

    Upside

    downward going graph

Haemonetics Corporation share price movements today

Previous Close
$85.02
Open
$85.04
Volume
479.9K
Day's Low - High
$84.92 - $87.68
52 Week Low - High
$47.32 - $88.59

Haemonetics Corporation Historical Returns

1 Month Return
+ 15.17 %
3 Month Return
+ 54.25 %
1 Year Return
+ 57.47 %
3 Year Return
-5.47 %
5 Year Return
+ 45.38 %

Haemonetics Corporation Stock Fundamentals & Key Indicators

Check Haemonetics Corporation market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$3.8B

EPS (TTM)

4.9433

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

41.59

Industry PE ratio

26.875

PEG Ratio

1.363

EBITDA

-

Revenue (TTM)

-

Profit Margin

7.29%

Return On Equity TTM

12.03%

Haemonetics Corporation Stock Valuation

Track how Haemonetics Corporation P/E has moved over time to understand its valuation trends.

Haemonetics Corporation in the last 5 years

  • Overview

  • Trends

Lowest (12.90x)

September 30, 2025

Industry (26.88x)

August 8, 2026

Today (41.59x)

August 8, 2026

Highest (27.62x)

December 31, 2022

LowHigh

Today’s Price to Earnings Ratio: 41.59x

Haemonetics Corporation vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Haemonetics Corporation with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$3.8B45.38%41.597.29%NA
BUY$129.3B28.52%34.8514.43%1.04%
BUY$51.6B-22.47%53.3315.43%NA
BUY$109.3B-33.21%23.0513.20%3.29%
BUY$184.1B-11.63%34.2111.65%2.35%

Stock Returns calculator for Haemonetics Corporation Stock including INR - Dollar returns

The Haemonetics Corporation stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Haemonetics Corporation investment value today

Current value as on today

₹1,77,034

Returns

₹77,034

(+77.03%)

Returns from Haemonetics Corporation Stock

₹62,697 (+62.7%)

Dollar Impact

₹14,337 (+14.34%)

Analyst Recommendation on Haemonetics Corporation Stock

Based on 11 analysts

BUY

72.73%

Buy

27.27%

Hold

0.00%

Sell

Based on 11 analysts, 72.73% of analysts recommend a 'BUY' rating for Haemonetics Corporation. Average target price of $87.9

Haemonetics Corporation Share Price Target

Get share price movements and forecasts by analysts on Haemonetics Corporation.

What analysts predicted

0.07%UPSIDE

Target Price

$87.9

Current Price

$87.84

Analyzed by

11 Analysts

Target

$87.90

Haemonetics Corporation target price $87.9, a slight upside of 0.07% compared to current price of $87.84. According to 11 analysts rating.

Indian Investors' Interest in Haemonetics Corporation Stock

Search interest for Haemonetics Corporation Stock has increased by 25% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:25% versus previous 30 day period

Haemonetics Corporation Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
336
343
336
345
348
330
321
327
338
346
Gross Profit
184
188
179
191
199
181
191
183
191
198
Operating Income
-
-
-
-
-
-
-
-
-
-
EBITDA
-
-
-
-
-
-
-
-
-
-
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-
-
-
-
-
-
-
-
-
-
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
31
20
38
33
37
57
34
38
44
-20
Net Profit Margin
9.29%
5.93%
11.41%
9.79%
10.76%
17.54%
10.59%
11.82%
13.20%
-5.82%

Haemonetics Corporation Annual Profit & Loss

All numbers in Millions USD

Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Total Revenue
886
903
967
988
870
993
1,168
1,309
1,360
1,334
Gross Profit
378
411
417
487
428
530
622
711
778
743
Operating Income
-
-
-
-
-
-
-
-
-
-
EBITDA
-
-
-
-
-
-
-
-
-
-
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-
-
-
-
-
-
-
-
-
-
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-26
45
55
76
79
43
115
117
167
97
Net Profit Margin
-2.96%
5.04%
5.69%
7.74%
9.13%
4.37%
9.87%
8.98%
12.32%
7.29%

Global Institutional Holdings in Haemonetics Corporation

Funds
Holdings
Fort Washington Investment Advisors Inc
1.83%
Schroder Investment Management Group
1.85%
Wellington Management Company LLP
4.46%
Invenomic Capital Management, LP
1.46%
Northern Trust Corp
1.27%

Haemonetics Corporation News & Key Events

  • img

    Today's Timeline - 28 July

    Wed, 01:03 AM

    -

    Haemonetics reports flat sales growth and subscale operations, indicating need for strategic improvements.

    Wed, 02:26 AM

    -

    Haemonetics director awarded 2,538 RSUs, impacting share dilution and potential insider selling.

Insights on Haemonetics Corporation

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, HAE stock has moved up by 54.2%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 4 quarters, 321.39M → 346.35M (in $), with an average increase of 2.5% per quarter

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, HAE has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Stryker Corporation has given 13.7% return, outperforming this stock by 19.2%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 44.73M → -20.14M (in $), with an average decrease of 145.0% per quarter

About Haemonetics Corporation

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
OrganisationHaemonetics Corporation
Headquarters125 Summer Street, Boston, MA, United States, 02110
IndustryMedical Devices
CEOMr. Christopher A. Simon
E-voting on sharesClick here to vote

Key Management of Haemonetics Corporation

Name

Title

Mr. James C. D'Arecca CPA

CFO, Executive VP & Financial Officer

Ms. Michelle L. Basil Esq., J.D.

Executive VP, General Counsel & Secretary

Mr. Roy Galvin

Executive VP & Chief Commercial Officer

Mr. Josh Gitelson

Senior Director of Global Communications

Mr. Rajeev Varma

Senior Vice President of Strategy & Corporate Development

Ms. Laurie A. Miller

Senior VP & Chief Human Resources Officer

Mr. Christopher A. Simon

CEO, President & Director

Mr. Frank W. Chan Ph.D.

Executive VP & COO

Ms. Farris Maryanne E. Maunsell

VP, Chief Accounting Officer & Principal Accounting Officer

Ms. Olga Guyette

VP of IR & Treasury

FAQs

What is Haemonetics Corporation share price today?

Haemonetics Corporation share price today is $87.84 as on at the close of the market. Haemonetics Corporation share today touched a day high of $87.68 and a low of $84.92.

What is the 52 week high and 52 week low for Haemonetics Corporation share?

Haemonetics Corporation share touched a 52 week high of $88.59 on and a 52 week low of $47.32 on . Haemonetics Corporation stock price today i.e. is closed at $87.84,which is 0.84% down from its 52 week high and 85.65% up from its 52 week low.

What is Haemonetics Corporation's market capitalisation today?

Haemonetics Corporation market capitalisation is $0.00T as on .

How to invest in Haemonetics Corporation Stock (HAE) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Haemonetics Corporation on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Haemonetics Corporation Shares that will get you 0.0171 shares as per Haemonetics Corporation share price of $87.84 per share as on August 8, 2026 at 8:46 am IST.

What is the minimum amount required to buy Haemonetics Corporation Stock (HAE) from India?

Indian investors can start investing in Haemonetics Corporation (HAE) shares with as little as ₹95.198 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹951.98 in Haemonetics Corporation stock (as per the Rupee-Dollar exchange rate as on ). Based on Haemonetics Corporation share’s latest price of $87.84 as on August 8, 2026 at 8:46 am IST, you will get 0.1138 shares of Haemonetics Corporation. Learn more about fractional shares .

What are the returns that Haemonetics Corporation has given to Indian investors in the last 5 years?

Haemonetics Corporation stock has given 45.38% share price returns and 27.7% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?